Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS
03:14am, Sunday, 26'th Apr 2026
Abacus FCF Advisors LLC bought a new position in shares of Alkermes plc (NASDAQ: ALKS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Alkermes to Report First Quarter Financial Results on May 5, 2026
04:05pm, Tuesday, 21'st Apr 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adu
Top 2 Health Care Stocks That May Implode In April
08:34am, Wednesday, 01'st Apr 2026
As of April 1, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
07:35am, Wednesday, 01'st Apr 2026
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech lands
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
07:00am, Wednesday, 01'st Apr 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo i
Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts
02:23am, Tuesday, 31'st Mar 2026
Alkermes plc (NASDAQ: ALKS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen brokerages that are currently covering the company, MarketBeat Ratings re
Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?
12:32pm, Friday, 27'th Mar 2026
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS
03:07am, Saturday, 14'th Mar 2026
Avoro Capital Advisors LLC reduced its holdings in Alkermes plc (NASDAQ: ALKS) by 22.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (S
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
07:00am, Thursday, 12'th Mar 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2
New Strong Sell Stocks for March 11th
06:15am, Wednesday, 11'th Mar 2026
ALKS, BBSI and CBZ have been added to the Zacks Rank #5 (Strong Sell) List on March 11th, 2026.
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
04:00pm, Tuesday, 10'th Mar 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET
Alkermes plc $ALKS Shares Bought by Artisan Partners Limited Partnership
04:25am, Saturday, 28'th Feb 2026
Artisan Partners Limited Partnership grew its stake in shares of Alkermes plc (NASDAQ: ALKS) by 36.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutio
Alkermes Q4 Earnings Call Highlights
02:38am, Saturday, 28'th Feb 2026
Alkermes (NASDAQ: ALKS) executives highlighted a "strong and eventful" 2025 and outlined a 2026 plan focused on expanding the company's commercial platform following its Avadel acquisition while advan
